Exelixis, Inc. SEC filings EXEL

Exelixis, Inc. has 1,003 filings in SEC EDGAR's recent list, going back to Mar 2, 2018. Its latest annual report, Form 10-K, was filed on Feb 10, 2026 for the period ended Jan 2, 2026. The latest quarterly report (Form 10-Q) was filed on Oct 29, 2026, covering the quarter ended Oct 2, 2026. The most recent current report (Form 8-K) was filed on Oct 29, 2026 (results of operations). The company's fiscal year ends on January 1.

Form Description Filed Period
10-K Annual report Feb 10, 2026 Jan 2, 2026
ARS Annual report to shareholders Apr 16, 2025 Jan 3, 2025
10-K Annual report Feb 11, 2025 Jan 3, 2025
ARS Annual report to shareholders Apr 18, 2024 Dec 31, 2023
10-K Annual report Feb 6, 2024 Dec 29, 2023
ARS Annual report to shareholders May 2, 2023 Dec 30, 2022
10-K Annual report Feb 7, 2023 Dec 30, 2022
10-K Annual report Feb 18, 2022 Dec 31, 2021
10-K Annual report Feb 11, 2021 Jan 1, 2021
10-K Annual report Feb 25, 2020 Jan 3, 2020
10-K Annual report Feb 22, 2019 Dec 28, 2018

Showing 11 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as
EXEL (Nasdaq)
Fiscal year ends
January 1
Incorporated in
DE
Headquarters
Alameda, CA
SEC filer status
Large accelerated filer
SEC CIK
939767
Former names
EXELIXIS INC (until Sep 12, 2012)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.